Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Immunoglobulin G · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment B, followed by Treatment A. |
| Sequence 2 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment A, followed by Treatment C. |
| Sequence 3 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment D, followed by Treatment C. |
| Sequence 4 | EXPERIMENTAL | Participants will receive SC administrations of IgG into the abdominal region starting with Treatment B, followed by Treatment D. |
| Name | Type | Description |
|---|---|---|
| Immunoglobulin G | DRUG | Participants will receive SC administrations of IgG |
Inclusion Criteria: * Body mass index (BMI) 18 to 36 kilograms per meter square (kg/m\^2), inclusive * For females of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during IgG administration and for 28 days after completio...
Immunoglobulin G is an investigational small molecule therapeutic being developed by Roche Holding AG. It is in Phase 1 clinical development, with one completed trial conducted in healthy participants. The specific disease indications for which it is being studied have not been disclosed.
Immunoglobulin G is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is responsible for advancing the asset through clinical development, and it has completed one Phase 1 trial of the therapy in healthy participants.
Immunoglobulin G is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA for any indication.
Immunoglobulin G has been evaluated in one completed Phase 1 trial, NCT07025577. The study assessed the tolerability and safety of subcutaneously administered Immunoglobulin G with varying injection conditions in 82 healthy participants in the United States. It was randomized and controlled but not double blind.
Immunoglobulin G is being studied as an investigational therapy, but the specific indications have not been disclosed. Its completed Phase 1 trial enrolled healthy participants rather than patients with a defined disease, so no therapeutic indication has been publicly specified.